Carbone A, Gloghini A: KSHV/HHV8-associated lymphomas. Br J Haematol. 2008, 140 (1): 13-24.
PubMed
Google Scholar
Boulanger E, Daniel MT, Agbalika F, Oksenhendler E: Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol. 2003, 73 (3): 143-148.
Article
CAS
PubMed
Google Scholar
Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL: The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol. 1996, 13 (3): 215-226.
Article
CAS
PubMed
Google Scholar
Morassut S, Vaccher E, Balestreri L, Gloghini A, Gaidano G, Volpe R, Tirelli U, Carbone A: HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients. Radiology. 1997, 205 (2): 459-463.
Article
CAS
PubMed
Google Scholar
Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996, 88 (2): 645-656.
CAS
PubMed
Google Scholar
Ansari MQ, Dawson DB, Nador R, Rutherford C, Schneider NR, Latimer MJ, Picker L, Knowles DM, McKenna RW: Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol. 1996, 105 (2): 221-229.
Article
CAS
PubMed
Google Scholar
Otsuki T, Kumar S, Ensoli B, Kingma DW, Yano T, Stetler-Stevenson M, Jaffe ES, Raffeld M: Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. Leukemia. 1996, 10 (8): 1358-1362.
CAS
PubMed
Google Scholar
Karcher DS, Alkan S: Human herpesvirus-8-associated body cavity-based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm. Hum Pathol. 1997, 28 (7): 801-808.
Article
CAS
PubMed
Google Scholar
Valencia ME, Martinez P, Moreno V, Laguna F, Lahoz JG: AIDS-related body cavity-based lymphomas, herpesvirus-8 and HIV infection: a study of seven cases. Aids. 1999, 13 (18): 2603-2605.
Article
CAS
PubMed
Google Scholar
Boulanger E, Agbalika F, Maarek O, Daniel MT, Grollet L, Molina JM, Sigaux F, Oksenhendler E: A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J. 2001, 2 (3): 172-179.
Article
CAS
PubMed
Google Scholar
Chen YB, Rahemtullah A, Hochberg E: Primary effusion lymphoma. Oncologist. 2007, 12 (5): 569-576.
Article
PubMed
Google Scholar
Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M: A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006, 17 (12): 1849-1850.
Article
CAS
PubMed
Google Scholar
An J, Sun Y, Fisher M, Rettig MB: Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004, 18 (10): 1699-1704.
Article
CAS
PubMed
Google Scholar
Flaberg E, Stuber G, Szekely L: Multi-dimensional laser confocal microscopy on live cells in submicroliter volumes using glass capillaries. Acta Histochem Cytochem. 2006, 39 (4): 103-106.
Article
PubMed
PubMed Central
Google Scholar
Flaberg E, Sabelstrom P, Strandh C, Szekely L: Extended Field Laser Confocal Microscopy (EFLCM): combining automated Gigapixel image capture with in silico virtual microscopy. BMC Med Imaging. 2008, 8: 13-
Article
PubMed
PubMed Central
Google Scholar
Markasz L, Kis LL, Stuber G, Flaberg E, Otvos R, Eksborg S, Skribek H, Olah E, Szekely L: Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel. Leuk Lymphoma. 2007, 48 (9): 1835-1845.
Article
CAS
PubMed
Google Scholar
Markasz L, Stuber G, Flaberg E, Jernberg AG, Eksborg S, Olah E, Skribek H, Szekely L: Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer. 2006, 6: 265-
Article
PubMed
PubMed Central
Google Scholar
Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, Masszi T, Kozma A, Adam E, Miseta A, et al: Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol. 2010, 38 (12): 1219-1230.
Article
CAS
PubMed
Google Scholar
de Hoon MJ, Imoto S, Nolan J, Miyano S: Open source clustering software. Bioinformatics. 2004, 20 (9): 1453-1454.
Article
CAS
PubMed
Google Scholar
Cersosimo RJ, Hong WK: Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986, 4 (3): 425-439.
CAS
PubMed
Google Scholar
Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC: High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004, 100 (8): 1724-1733.
Article
CAS
PubMed
Google Scholar
Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G, Liliemark J: Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res. 1998, 4 (3): 653-658.
CAS
PubMed
Google Scholar
Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD: Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol. 1986, 17 (3): 277-280.
Article
CAS
PubMed
Google Scholar
Chan GL, Erdmann GR, Gruber SA, Stock P, Chen S, Ascher NL, Canafax DM: Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Eur J Clin Pharmacol. 1989, 36 (3): 265-271.
Article
CAS
PubMed
Google Scholar
Gruber A, Liliemark E, Tidefelt U, Paul C, Bjorkholm M, Peterson C, Liliemark J: Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. Leuk Res. 1995, 19 (10): 757-761.
Article
CAS
PubMed
Google Scholar
Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, Costa M, Mairone L, Zara GP, Fornari G, Eandi M: Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res. 2004, 50 (2): 173-179.
Article
CAS
PubMed
Google Scholar
Fogli S, Danesi R, Gennari A, Donati S, Conte PF, Del Tacca M: Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol. 2002, 13 (6): 919-927.
Article
CAS
PubMed
Google Scholar
GlaxoSmithKline Research Triangle Park N: Prescribing Information Leukeran®. [http://www.drugs.com/monograph/leukeran.html]
Ghazal-Aswad S, Calvert AH, Newell DR: A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol. 1996, 37 (5): 429-434.
Article
CAS
PubMed
Google Scholar
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000, 6 (4): 1205-1218.
CAS
PubMed
Google Scholar
Rischin D, Ackland SP, Smith J, Garg MB, Clarke S, Millward MJ, Toner GC, Zalcberg J: Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann Oncol. 2002, 13 (11): 1810-1818.
Article
CAS
PubMed
Google Scholar
Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, et al: A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res. 2004, 10 (14): 4724-4733.
Article
CAS
PubMed
Google Scholar
Desai ZR, Van den Berg HW, Bridges JM, Shanks RG: Can severe vincristine neurotoxicity be prevented?. Cancer Chemother Pharmacol. 1982, 8 (2): 211-214.
Article
CAS
PubMed
Google Scholar
Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003, 21 (1): 35-40.
CAS
PubMed
Google Scholar
Andersson B, Andersson I, Beran M, Ehrsson H, Eksborg S: Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979, 2 (1): 15-17.
Article
CAS
PubMed
Google Scholar
Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U, Vaccher E: Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol. 2004, 15 (12): 1805-1809.
Article
CAS
PubMed
Google Scholar
Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, Howe K, Chisholm JC, Beane C, Brennan B, et al: Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res. 2005, 11 (16): 5893-5899.
Article
CAS
PubMed
Google Scholar
Peng YM, Alberts DS, Chen HS, Mason N, Moon TE: Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. Br J Cancer. 1980, 41 (4): 644-647.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kozuch P, Hoff PM, Hess K, Adams J, Newman RA, Lee F, Pazdur R: Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 2001, 91 (4): 815-821.
Article
CAS
PubMed
Google Scholar
Yan JH, Ataga K, Kaul S, Olson JS, Grasela DM, Gothelf S, Kutlar A, Orringer E: The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol. 2005, 45 (4): 434-445.
Article
CAS
PubMed
Google Scholar
Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, et al: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res. 1999, 5 (1): 69-75.
CAS
PubMed
Google Scholar
Ylikangas P, Mononen I: Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation. Ther Drug Monit. 2002, 24 (4): 502-506.
Article
CAS
PubMed
Google Scholar
Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004, 22 (11): 2108-2121.
Article
CAS
PubMed
Google Scholar
Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J: Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr. 2005, 40 (5): 573-580.
Article
CAS
PubMed
Google Scholar